Evaluate Vantage

Evaluate Vantage holds market forecasts, deal analysis and readout scorecards for oncology assets, forecasting which drugs and modalities will matter commercially in the next decade. It is published by Evaluate, part of Norstella, with weekly analysis; the oncology market forecast to 2036 is the reference for investors. Access is freemium, with an Evaluate subscription for the underlying data. On OnCo it is listed as a source with the tags source, news and data.